ABVC BioPharma, Inc.
ABVC
$2.41
-$0.12-4.74%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 809.60K | 402.90K | 520.00K | 521.20K | 660.00K |
| Total Other Revenue | -11.60K | -2.30K | -2.30K | -2.30K | -141.00K |
| Total Revenue | 798.00K | 391.30K | 508.40K | 509.60K | 509.80K |
| Cost of Revenue | 0.00 | 300.00 | 500.00 | 800.00 | 140.00K |
| Gross Profit | 798.00K | 391.00K | 508.00K | 508.90K | 369.90K |
| SG&A Expenses | 5.16M | 3.88M | 2.56M | 4.66M | 4.66M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 43.30K | 52.60K | 52.60K | 52.60K | 5.90K |
| Total Operating Expenses | 5.33M | 4.07M | 2.75M | 4.90M | 5.03M |
| Operating Income | -4.53M | -3.68M | -2.24M | -4.39M | -4.52M |
| Income Before Tax | -4.41M | -3.61M | -2.46M | -4.44M | -5.10M |
| Income Tax Expenses | 24.10K | 24.00K | -110.50K | -110.50K | 64.80K |
| Earnings from Continuing Operations | -4.44 | -3.64 | -2.35 | -4.33 | -5.16 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 319.30K | 371.00K | 400.30K | 391.70K | 608.30K |
| Net Income | -4.12M | -3.26M | -1.95M | -3.94M | -4.55M |
| EBIT | -4.53M | -3.68M | -2.24M | -4.39M | -4.52M |
| EBITDA | -4.50M | -3.65M | -2.20M | -4.36M | -4.49M |
| EPS Basic | -0.22 | -0.20 | -0.15 | -0.39 | -0.46 |
| Normalized Basic EPS | -0.12 | -0.10 | -0.08 | -0.22 | -0.22 |
| EPS Diluted | -0.22 | -0.20 | -0.15 | -0.39 | -0.46 |
| Normalized Diluted EPS | -0.12 | -0.10 | -0.08 | -0.22 | -0.22 |
| Average Basic Shares Outstanding | 68.81M | 57.96M | 51.90M | 46.67M | 40.14M |
| Average Diluted Shares Outstanding | 68.81M | 57.96M | 51.90M | 46.67M | 40.14M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |